Enterome vs Lysoway Therapeutics
Enterome vs Lysoway Therapeutics, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Enterome is on 60/100 and Lysoway Therapeutics on 48/100.
Where each one leads
Enterome
- our overall score: 60/100 against 48/100
- funding raised: $124M against $45.0M
- LinkedIn following: 16,846 against 1,282
Lysoway Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Enterome | Lysoway Therapeutics |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases. | Developing small-molecule modulators of lysosomal ion channels for neurodegenerative diseases. |
| Category | Biotechnology, Drug Discovery, Oncology, Immunotherapy | Biotechnology, Pharmaceuticals, Healthcare, Neuroscience |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Services |
| Founded | 2012 | 2021 |
| Headquarters | Paris, France | Cambridge, USA |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Enterome | Lysoway Therapeutics |
|---|---|---|
| Employees | 33 | Not published |
| Total funding | $124M | $45.0M |
| Latest round | Later Stage VC | Series A |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 16,846 | 1,282 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Enterome | Lysoway Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 48/100 |
| Traction | 55/100 | 38/100 |
| Team | 70/100 | Not published |
| Community | Not published | 15/100 |
| Search visibility | 34/100 | 20/100 |
| Quality | 68/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | Not published |
| Domain ratingLink authority, 0-100 | 46/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Enterome | Lysoway Therapeutics |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CMS | WordPress | Not detected |
| Frameworks | Bootstrap | Not detected |
| Analytics | Google Analytics 4, Segment | Not detected |
Enterome vs Lysoway Therapeutics: common questions
Which is better, Enterome or Lysoway Therapeutics?
On our 0-100 score Enterome rates higher (60/100 against 48/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Enterome and Lysoway Therapeutics compare on the numbers?
Enterome leads on our overall score (60/100 against 48/100), funding raised ($124M against $45.0M), LinkedIn following (16,846 against 1,282).
Read the full Enterome review and pricing or the Lysoway Therapeutics review and pricing. You can also browse other Enterome alternatives we track.